Terms: = Head and neck cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4
99 results:
1. her4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract] [Full Text] [Related]
2. Effects of a mucoadhesive phytomedicine (Curcuma longa L. and Bidens pilosa L.) on radiotherapy-induced oral mucositis and quality of life of patients undergoing head and neck cancer treatment: randomized clinical trial.
Martins AFL; Pereira CH; Morais MO; de Sousa-Neto SS; Valadares MC; Freitas NMA; Leles CR; de Mendonça EF
Support Care Cancer; 2023 Aug; 31(9):517. PubMed ID: 37566179
[TBL] [Abstract] [Full Text] [Related]
3. The Effect of Metformin on Vestibular Schwannoma Growth: A Systematic Review and Meta-analysis.
Lovin BD; Wilkinson AJ; Qing Y; Hernandez M; Nader ME; Raza S; DeMonte F; Gidley PW
Laryngoscope; 2023 Sep; 133(9):2066-2072. PubMed ID: 36744870
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis.
Wang L; Liu D; Wei D
Comput Math Methods Med; 2022; 2022():5145549. PubMed ID: 36060662
[TBL] [Abstract] [Full Text] [Related]
5. Immunological and Genetic Characterization of Patients With head and neck cancer who Developed Recurrence.
Yasui K; Kondou R; Miyata H; Iizuka A; Ashizawa T; Nagashima T; Ohshima K; Urakami K; Muramatsu K; Sugino T; Yamaguchi K; Ogawa H; Onoe T; Harada H; Asakura H; Murayama S; Nishimura T; Goto S; Okada S; Mukaigawa T; Hamauchi S; Yokota T; Onozawa Y; Akiyama Y
Anticancer Res; 2022 Sep; 42(9):4417-4428. PubMed ID: 36039416
[TBL] [Abstract] [Full Text] [Related]
6. Characteristics and interplay of esophageal microbiota in esophageal squamous cell carcinoma.
Lin Z; Rao W; Xiang Z; Zeng Q; Liu S; Yu K; Zhou J; Wang J; Chen W; Chen Y; Peng X; Hu Z
BMC Cancer; 2022 Jun; 22(1):696. PubMed ID: 35739509
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of EVT6-NTRK3-Dependent Papillary Thyroid cancer Using Minor Expression Profile.
Kechin AA; Ivanov AA; Kel AE; Kalmykov AS; Oskorbin IP; Boyarskikh UA; Kharpov EA; Bakharev SY; Oskina NA; Samuilenkova OV; Vikhlyanov IV; Kushlinskii NE; Filipenko ML
Bull Exp Biol Med; 2022 Jun; 173(2):252-256. PubMed ID: 35737155
[TBL] [Abstract] [Full Text] [Related]
8. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
9. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI; Chambers E; Nguyen T; Coolidge A; Lydon CA; Le X; Sholl L; Heymach JV; Nishino M; Van Allen EM; Jänne PA
J Thorac Oncol; 2022 Jun; 17(6):779-792. PubMed ID: 35331964
[TBL] [Abstract] [Full Text] [Related]
10. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
[TBL] [Abstract] [Full Text] [Related]
11. miR-551b is Associated with the Poor Prognosis and Malignant Development of Papillary Thyroid cancer Through Regulating erbb4.
Wang J; Liu H
Horm Metab Res; 2022 Feb; 54(2):113-118. PubMed ID: 35130572
[TBL] [Abstract] [Full Text] [Related]
12. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
13. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks.
Gulfidan G; Soylu M; Demirel D; Erdonmez HBC; Beklen H; Ozbek Sarica P; Arga KY; Turanli B
Arch Biochem Biophys; 2022 Jan; 715():109085. PubMed ID: 34800440
[TBL] [Abstract] [Full Text] [Related]
14. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR
Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763
[TBL] [Abstract] [Full Text] [Related]
15. Lateral Lymph Node Metastases in T1a Papillary Thyroid Carcinoma: Stratification by Tumor Location and Size.
Zhang X; Chen W; Fang Q; Fan J; Feng L; Guo L; Liu S; Ge H; Du W
Front Endocrinol (Lausanne); 2021; 12():716082. PubMed ID: 34335480
[TBL] [Abstract] [Full Text] [Related]
16. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and her4 in a differential specificity: Implications for targeted esophageal cancer therapy.
Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
[TBL] [Abstract] [Full Text] [Related]
17. A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets.
Yang X; Miao Y; Wang J; Mi D
Life Sci; 2021 May; 273():119307. PubMed ID: 33691171
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic value of MRI-determined cervical lymph node size in nasopharyngeal carcinoma.
Huang CL; Chen Y; Guo R; Mao YP; Xu C; Tian L; Liu LZ; Lin AH; Sun Y; Ma J; Tang LL
Cancer Med; 2020 Oct; 9(19):7100-7106. PubMed ID: 32794334
[TBL] [Abstract] [Full Text] [Related]
19. miR-326 inhibits the progression of papillary thyroid carcinoma by targeting MAPK1 and erbb4.
Nie FR; Li QX; Wei HF; Ma Y
Neoplasma; 2020 May; 67(3):604-613. PubMed ID: 32266816
[TBL] [Abstract] [Full Text] [Related]
20. Relevance and actionable mutational spectrum in oral squamous cell carcinoma.
Jayaprakash C; Varghese VK; Jayaram P; Chakrabarty S; Kudva A; Ray S; Satyamoorthy K
J Oral Pathol Med; 2020 May; 49(5):427-434. PubMed ID: 31845386
[TBL] [Abstract] [Full Text] [Related]
[Next]
